FATE1 and adrenal cortex carcinoma: As a consequence, FATE1 upregulation, like in adrenocortical carcinoma cells, results in cell-death resistance not only in response to pro-apoptotic stimuli that impinge on ER–mitochondrial Ca2+ signaling but also in response to mitotane, a chemotherapeutic drug clinically used in the treatment of patients with adrenocortical cancer.